Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

Core Points - A proposed settlement of $10.5 million has been reached for all individuals or entities who purchased ImmunityBio, Inc. securities between March 10, 2021, and May 10, 2023 [1][2] - The settlement aims to resolve allegations of material misrepresentations and omissions regarding ImmunityBio's compliance with manufacturing practices and product approval prospects [3] Settlement Details - The settlement class excludes defendants, their immediate family members, subsidiaries, affiliates, and any controlling persons or entities [2] - A hearing is scheduled for June 13, 2025, to determine the fairness and adequacy of the proposed settlement and the plan for allocating the settlement proceeds [1][3] Claims and Objections - Settlement class members must submit a Proof of Claim and Release Form by July 7, 2025, to participate in the distribution of the settlement fund [4] - Members wishing to exclude themselves from the settlement must submit a request by May 23, 2025 [5] - Settlement class members have the right to object to the settlement and related requests, with objections due by May 23, 2025 [6] Additional Information - Detailed documents regarding the settlement can be obtained online or by contacting the claims administrator [7] - The notice is dated April 7, 2025, and is issued by the United States District Court for the Southern District of California [8]